STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNTA
  4. [Form 3] Genenta Science S.p.A. Initial Statement of Beneficial Ownership

Genenta Science S.p.A. (GNTA) director discloses ADS stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Genenta Science S.p.A. director Sharei Armon has reported initial holdings consisting solely of stock options linked to American Depositary Shares (ADSs). These include options over 20,163 ADSs at an exercise price of $3.0800 per share, which became fully vested and exercisable on July 1, 2024.

Armon also holds options over 20,000 ADSs at an exercise price of $4.3600, vesting in equal monthly installments over one year beginning June 4, 2025, and options over 10,000 ADSs at $1.4800, vesting monthly over one year beginning December 18, 2025. Each ADS represents one ordinary share of Genenta.

Positive

  • None.

Negative

  • None.
Insider Sharei Armon
Role Director
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Ordinary Shares -- -- --
holding American Depositary Shares ("ADSs") -- -- --
Holdings After Transaction: Stock Option (right to buy) — 20,163 shares (Direct); Ordinary Shares — 0 shares (Direct); American Depositary Shares ("ADSs") — 0 shares (Direct)
Footnotes (1)
  1. Each American Depositary Share represents one ordinary share, no par value, of the Issuer. Options on 20,163 shares became fully vested and exercisable on July 1, 2024. The stock options vest in equal monthly installments over one year beginning June 4, 2025. The stock options vest in equal monthly installments over one year beginning December 18, 2025.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Sharei Armon
(Last)(First)(Middle)
27 BRUNSWICK ROAD
(Street)
ARLINGTON, MASSACHUSETTS 02476
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares0D
American Depositary Shares ("ADSs")(1)0D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)07/01/2024(2)07/01/2034ADSs20,163$3.08D
Stock Option (right to buy)06/04/2025(3)06/04/2035ADSs20,000$4.36D
Stock Option (right to buy)12/18/2025(4)12/18/2035ADSs10,000$1.48D
Explanation of Responses:
1. Each American Depositary Share represents one ordinary share, no par value, of the Issuer.
2. Options on 20,163 shares became fully vested and exercisable on July 1, 2024.
3. The stock options vest in equal monthly installments over one year beginning June 4, 2025.
4. The stock options vest in equal monthly installments over one year beginning December 18, 2025.
/s/ Armon R. Sharei03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Genenta Science (GNTA) director Sharei Armon report on this Form 3?

Sharei Armon reports initial holdings of stock options tied to Genenta Science ADSs. These options, if exercised, entitle the director to acquire ADSs representing ordinary shares, with specific exercise prices, vesting schedules, and long-dated expiration terms disclosed.

How many Genenta Science (GNTA) ADSs are covered by Sharei Armon’s stock options?

The filing shows options over 20,163 ADSs at $3.0800, 20,000 ADSs at $4.3600, and 10,000 ADSs at $1.4800. In total, these derivative awards relate to 50,163 ADSs, each representing one ordinary share of Genenta Science.

When do Sharei Armon’s Genenta (GNTA) stock options vest and become exercisable?

Options on 20,163 shares became fully vested and exercisable on July 1, 2024. Additional options on 20,000 shares vest in equal monthly installments over one year beginning June 4, 2025, and options on 10,000 shares vest monthly over one year beginning December 18, 2025.

What are the exercise prices and expirations of Sharei Armon’s Genenta (GNTA) options?

Armon holds options at exercise prices of $3.0800, $4.3600, and $1.4800 per ADS. These options have expiration dates on July 1, 2034, June 4, 2035, and December 18, 2035, respectively, providing long-term potential equity exposure.

Does Sharei Armon directly hold any Genenta Science (GNTA) ordinary shares or ADSs?

The Form 3 indicates zero directly held ordinary shares and zero directly held ADSs for Sharei Armon. The reported economic exposure comes entirely from stock options over ADSs, which can be exercised in the future subject to vesting and payment of the exercise prices.